Program 50. česko-slovenské psychofarmakologické ... - Úvod

thursday 10 th january 2008 - cont.
Tůma I.: Cognitive symptoms of schizophrenia as a treatment target
Volavka J.: Subtyping of aggressive behavior in schizophrenia and its implications for
treatment
12,30 pm – 2,00pm SATELITTE SYMPOSIA (Congress Hall, „HRAD“ Building)
Bristol-Myers Squibb, spol. s r.o.: What to expect from effective antipsychotics -
clinical evidence
Fleischhacker W.: From efficacy to effectiveness - new treatment goals in schizophrenia
Mohr P.: Aripiprazole: two years after
2,00 pm – 2,45 pm POSTER SESSIONS I. (Winter Garden, Priessnitz Hotel)
Antipsychotics and Schizophrenia
1. Vrajová M., Peková S., Kalschka J., Šťastný F.:
Expression of hippocampal nr1 subunit of nmda receptor in humans suffering from
schizophrenia
2. Valeš K., Svoboda J., Bubeníková-Valešová V., Stuchlík A.:
Effect of mGluR agonist ACPD on cognitive deficit in animal model of psychosis-like behavior
3. Kenney J., Valeš K., Bubeníková-Valešová V., Stuchlík A.:
Effect of dopamine D1 agonist A77636 on active allothetic place avoidance, a spatial
cognition ask, in an animal model of schizophrenia
4. Stuchlík A., Petrásek T., Valeš K.:
Co-application of alpha1-adrenergic prazosine and D2 antagonist sulpiride results in
impairment of locomotion and spatial behavior in a place avoidance task
5. Verébová K., Novák T., Brunovský M., Mohr P., Španiel F., Tintěra J.,
Horáček J:
The influence of polymorphism (SNP A) for the gene DTNBP-1 on brain morphometry
and clinical phenotype in schizophrenia
6. Janatka J., Morávek S., Tichý V.:
Impaired glucose tolerance in patients treated with antipsychotics
7. Valchář M., Kassahun B., Kubeš V.:
The development of mass spectrometry method for the determination of D-serine in
human plasma
thursday 10 th january 2008 - cont.
8. Novák T., Klírová M., Brunovský M., Horáček J.:
The effect of low-frequency rTMS on electromagnetic tomography (LORETA) in the
treatment of auditory hallucinations
9. Ustohal L., Přikryl R., Venclíková S.:
Case study of a patient with negative symptoms of schizophrenia treated repeatedly
by repetitive transcranial magnetic stimulation
10. Španiel F., Hrdlička J., Novák T., Motlová L.:
ITAREPS: Information Technology Aided Relapse Prevention in Schizophrenia. Two
year follow-up.
11. Janů L., Racková S.:
The changes in the duration of hospitalisation and the antipsychotic doses during the
first years of schizophrenia. Retrospective analysis.
12. Racková S., Janů L.:
Are the first psychotic episodes influenced by the abusus of cannabinoids
Retrospective analysis.
13. Nawka A., Raboch J., Nawková L., Kitzlerová E., Kališová L., Černý M.,
Číhal L., Kallert TW.:
Quality of life and psychopathology in involuntarily treated patients with
schizophrenia
14. Lužný J., Přikrylová D., Lavická Z., Návarová H.:
Erectile dysfunction in patients treated with atypical antipsychotics – pioneer study
15. Kališová L., Raboch J., skupina EUNOMIA:
Medication administered in a situation of acute agitation-international comparison,
EUNOMIA Project
16. Černý M., Žukov I., Vevera J.:
Violent behavior and victimization of persons with schizophrenia – review of studies
17. Švarc J., Bakešová D.:
Which medication prevents homicide Analysis of schizophrenics disculpated from
homicide
18. Hartoš V.:
Reversible dementia caused by antipsychotics
19. Hýža M.:
Antipsychotics versus regimen: the impact on weight gain in inpatients